ESMO 2022 | SECOMBIT: 4-year OS and tPFS data and preliminary biomarker analysis

Paolo Ascierto, MD, National Tumor Institute Fondazione G. Pascale, Naples, Italy, presents 4-year overall survival (OS) results from the randomized Phase II SECOMBIT trial (NCT02631447). The trial investigated the best sequential strategy in BRAFV600-mutated metastatic melanoma and consisted of three parallel arms. Patients in Arm A received encorafenib plus binimetinib as targeted therapy (T-T) in the first-line, switching to ipilimumab plus nivolumab (I-O) after progression. Patients in Arm B received I-O as first-line and switched to T-T after progression. Patients in Arm C received treatment using the “sandwich” strategy of T-T in the first-line, followed by a planned switch to I-O after 8 weeks, and a further switch back to T-T after progression. The primary endpoint was overall survival (OS) and the 4-year OS results were 46% for Arm A, 64% for Arm B, and 59% for Arm C. For the secondary endpoint of total progression-free survival (tPFS), the 4-year results were 29% for Arm A, 55% for Arm B, and 54% for Arm C. Prof Ascierto also discusses sub-group and biomarker analyses from the trial and suggests that a planned switch could be a beneficial treatment strategy for these patients. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.